Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Kay

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
American Journal of Pharmaceutical Education|June 11, 2009
Post-PharmD industry fellowship opportunities and proposed guidelines for uniformityPaul A Larochelle, Dan K Giang, Matthew A Silva, et al.
Journal of Pharmaceutical Sciences|January 30, 2022
Effects of Transportation of IV Bags Containing Protein Formulations Via Hospital Pneumatic Tube System: Particle Characterization by Multiple MethodsVaida Linkuvienė, Emma L Ross, Lindsey Crawford, et al.
Studies in Health Technology and Informatics|August 28, 2014
Interoperability standards enabling cross-border patient summary exchangeCatherine Chronaki, Ana Estelrich, Giorgio Cangioli, et al.
Current Medical Research and Opinion|July 11, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1LKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Future Oncology (London, England)|May 24, 2022
Indirect comparisons of brigatinib and alectinib for front-line <i>ALK</i>-positive non-small-cell lung cancerKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
American Journal of Pharmaceutical Education|June 11, 2009
Post-PharmD industry fellowship opportunities and proposed guidelines for uniformityPaul A Larochelle, Dan K Giang, Matthew A Silva, et al.
Journal of Pharmaceutical Sciences|January 30, 2022
Effects of Transportation of IV Bags Containing Protein Formulations Via Hospital Pneumatic Tube System: Particle Characterization by Multiple MethodsVaida Linkuvienė, Emma L Ross, Lindsey Crawford, et al.
Studies in Health Technology and Informatics|August 28, 2014
Interoperability standards enabling cross-border patient summary exchangeCatherine Chronaki, Ana Estelrich, Giorgio Cangioli, et al.
Current Medical Research and Opinion|July 11, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1LKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Future Oncology (London, England)|May 24, 2022
Indirect comparisons of brigatinib and alectinib for front-line <i>ALK</i>-positive non-small-cell lung cancerKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Pageof 3